Pharmacogenomics in solid tumors: Integrating germline and somatic genetic variability for precision oncology
GSC Biological and Pharmaceutical Sciences · 31.03.2026 · 34 (3) · 247-254
DOI: 10.30574/gscbps.2026.34.3.0096 ↗Kurz gefasst
Fachartikel in der Zeitschrift GSC Biological and Pharmaceutical Sciences, online erschienen am 31.03.2026. Verfasst von Savita D. Patil und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Solid tumors exhibit substantial interindividual variability in therapeutic response and drug-related toxicity, which cannot be fully explained by clinical or tumor-specific factors alone. Pharmacogenomics has emerged as a critical component of precision oncology by elucidating how both germline and somatic genetic variability influence anticancer drug efficacy and safety.
Objective
This review provides a comprehensive and clinically oriented overview of pharmacogenomics in solid tumour’s, highlighting actionable gene–drug associations, translational relevance, implementation challenges, and emerging innovations shaping future oncology practice.
Methods
A narrative review of peer-reviewed literature published between 2020 and 2026 was conducted using PubMed, EMBASE, Web of Science, and Google Scholar. Human studies, systematic reviews, meta-analyses, and clinical guidelines focusing on pharmacogenomic biomarkers and gene–drug interactions in solid tumors were included.
Results
Germline variants in key drug-metabolizing enzymes, including CYP2D6, DPYD, and UGT1A1, significantly influence drug exposure, toxicity risk, and treatment outcomes across multiple solid tumors. Somatic alterations such as EGFR, KRAS, and BRCA1/2 mutations guide targeted therapy selection, resistance prediction, and tumor-agnostic treatment strategies. Despite robust evidence supporting pharmacogenomic-guided therapy, clinical implementation remains inconsistent due to infrastructural limitations, cost concerns, and gaps in clinician education.
Conclusion
Pharmacogenomics represents a foundational pillar of precision oncology by integrating host and tumor genetic information to optimize therapeutic decision-making. Advances in polygenic modeling, liquid biopsy technologies, artificial intelligence, and multi-omics integration are expected to accelerate clinical adoption. Systematic implementation of pharmacogenomics has the potential to improve treatment efficacy, reduce toxicity, and enhance patient outcomes in solid tumors.
Zitieren
APA
Patil, S. D., Kulthe, V. P., & Patil, H. B. (2026). Pharmacogenomics in solid tumors: Integrating germline and somatic genetic variability for precision oncology. GSC Biological and Pharmaceutical Sciences, 34(3), 247-254. https://doi.org/10.30574/gscbps.2026.34.3.0096
Vancouver
Patil SD, Kulthe VP, Patil HB. Pharmacogenomics in solid tumors: Integrating germline and somatic genetic variability for precision oncology. GSC Biological and Pharmaceutical Sciences. 2026;34(3):247-254. doi:10.30574/gscbps.2026.34.3.0096
BibTeX
@article{Patil2026,
author = {Patil, Savita D. and Kulthe, Varsha P. and Patil, Harshada B.},
title = {Pharmacogenomics in solid tumors: Integrating germline and somatic genetic variability for precision oncology},
journal = {GSC Biological and Pharmaceutical Sciences},
year = {2026},
volume = {34},
number = {3},
pages = {247--254},
doi = {10.30574/gscbps.2026.34.3.0096}
}
EUVIMED